Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Strem Chemicals - Nanomaterials for R&D

There is 1 related live offer.

Save 25% on magneTherm

Established leader in Biotechnology and Pharmaceutical Industries Joins nanoTox Board of Directors

Published on March 26, 2009 at 7:53 PM

nanoTox, the first company to provide complete risk analysis and profiling exclusively for nanoparticles, announced today that C. Richard Piazza has joined the board of directors of its parent company Nano Risk Assessment, Inc. Mr. Piazza is founder and CEO of private equity firm La Jolla Capital Partners, LLC and an established leader in the biotechnology and pharmaceutical industries.

"We look forward to gaining from Mr. Piazza’s vast knowledge," said Harry Bushong, president of nanoTox. "With his decades of experience leading prominent biotech and pharmaceutical companies to profitability, Mr. Piazza’s insights and direction will be instrumental in assuring the success of nanoTox."

Mr. Piazza’s extensive experience includes 37 years in healthcare, 16 years in pharmaceuticals and biotech and 21 years in regulated medical devices. Thirty-two years of his career were spent as CEO and in general management for both public and private companies directing turnarounds, takeovers and complex strategies to increase revenues, profitability and market share.

Mr. Piazza formed La Jolla Capital Partners, LLC (LCP) in 2004 to help biotech, pharmaceutical and medical device companies secure venture capital funding, helping companies and VCs navigate critical early development stages. During his tenure with LCP, Mr. Piazza also served as interim Chairman & CEO for biotechnology drug company Chemokine Therapeutics during a key management transition period, preparing the company for its Phase II trials.

Mr. Piazza also was president of Biolectron, Inc., an internationally renowned private high-tech orthopedic research and manufacturing company; president and CEO of Radius Health System Services & Supplies, a $150 million, multi-division business providing comprehensive healthcare services; president of private startup Stimetics; and CEO of Smith & Nephew Pharmaceuticals and VitaGen, the developer of the world’s first bioartificial liver.

In addition to nanoTox, Mr. Piazza serves on the boards of BioHouston, LipoNova, Zetiq Technologies (Director), GynTec (Chairman), Nexus Health Systems and Traumatec. He is an advisor to the MD Anderson Cancer Center Department of Technology Transfer.

Mr. Piazza attended the State University of New York, where he received undergraduate degrees in Business Administration, Economics and Speech Pathology and his Masters Degree in Economics.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit